Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2018-07-09 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Det japanska patentverket avser bevilja BioInvent patent relevant för bolagets plattform F.I.R.S.T.TM
Regulatory Filings Classification · 95% confidence The document is a press release dated July 9, 2018, announcing that the Japanese Patent Office intends to grant a patent relevant to BioInvent's F.I.R.S.T.TM platform. It details the patent scope, mentions similar patents granted elsewhere (EPO, Australia, Russia), and provides standard company background and contact information. The final paragraph explicitly states: "Denna information är sådan information som BioInvent International AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BioInvent International AB is obliged to disclose pursuant to the EU Market Abuse Regulation). This indicates a mandatory regulatory disclosure that is not a standard periodic report (10-K, IR) or a specific corporate action announcement (DIV, CAP, DIRS). Since it is a general regulatory announcement concerning intellectual property/business development that doesn't fit the other specific categories (like LTR for legal proceedings or TAR for M&A), the most appropriate fallback category is Regulatory Filings (RNS). The document length (2964 chars) is short, but it is the primary announcement itself, not an announcement *about* another report, so the RPA rule does not strictly apply here, although RNS is often used for such non-standard disclosures.
2018-07-09 Swedish
The Japanese patent office intends to grant BioInvent patent relevant to its F.I.R.S.T.TM platform
Regulatory Filings Classification · 95% confidence The document is a press release dated July 9, 2018, announcing that the Japanese patent office intends to grant a patent relevant to BioInvent's F.I.R.S.T.TM platform. It details the patent's scope, mentions corresponding patents in other jurisdictions, and includes standard company boilerplate information and contact details. The final paragraph states: "This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a brief announcement of a specific, non-financial corporate event (patent grant decision) mandated for public disclosure—fits best under the general 'Regulatory Filings' category (RNS), as it is not an Earnings Release (ER), a Capital/Financing Update (CAP), or a Legal Proceeding Report (LTR). It is a general regulatory disclosure.
2018-07-09 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement dated May 31, 2018, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). It explicitly states that the total number of shares has increased due to the exercise of warrants, resulting in an increase of 400,478 shares. This directly relates to a change in the company's capital structure or share count. This aligns best with the 'Share Issue/Capital Change' category (SHA), which covers announcements regarding new share issues or capital changes. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The final sentence confirms it is a mandatory public disclosure regarding financial instruments, but the content is specifically about share count change.
2018-05-31 Swedish
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated May 31, 2018, announcing a change in the total number of shares and votes due to the exercise of warrants. This directly relates to a change in the company's capital structure (share count). This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. Although it is a press release, the core subject matter is a capital structure update, making SHA more specific than the general 'RPA' or 'RNS'. The document length is relatively short (2309 chars), but the content is the primary announcement itself, not just an announcement *about* another report.
2018-05-31 English
BioInvent ready to start a Phase I/IIa study of BI-1206 in combination with rituximab in patients with non-Hodgkin lymphoma
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 9, 2018. It announces that BioInvent has received authorization to start a new Phase I/IIa clinical study for its drug candidate BI-1206. This type of announcement, detailing operational progress, clinical trial initiation, and management commentary, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing operational/clinical progress rather than a formal financial report (like 10-K or IR) or a specific capital event, it fits best under the 'Earnings Release' category (ER) which often includes operational highlights, or potentially 'Regulatory Filings' (RNS) if it were purely regulatory. Given the content focuses on clinical trial progress and quotes management, ER is the most appropriate fit for a press release detailing operational milestones, even if it's not strictly quarterly earnings figures. It is not a formal financial report, a management discussion (MDA), or a capital event (CAP).
2018-05-09 English
BioInvent redo att inleda en fas I/IIa-studie med BI-1206 i kombination med rituximab i patienter med non-Hodgkins lymfom
Earnings Release Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated May 9, 2018. It announces that BioInvent has received authorization from the Swedish Medical Products Agency (Läkemedelsverket) to initiate a new clinical trial (Phase I/IIa study with BI-1206 in combination with rituximab). This type of announcement, detailing operational progress, clinical trial initiation, and management commentary, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific operational update rather than a comprehensive financial report (like 10-K or IR) or a formal regulatory filing notification, and it contains key operational highlights, 'ER' (Earnings Release) is the closest fit among the provided options for a major company announcement, although 'RNS' (Regulatory Filings) is also plausible for non-standard announcements. Given the content focuses on clinical trial progress and strategic updates, which often accompany earnings periods or serve as significant news updates, ER is selected as the primary classification for a major operational press release. The final paragraph confirms it is information the company is obligated to disclose under EU market abuse regulation, reinforcing its status as a significant public disclosure. FY 2018
2018-05-09 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.